Showing results (1541-1550 of 3,473) with videos related to

Sort By:
Pageof 348
Clinical Pharmacokinetics|December 23, 2016
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia AAnita Shah, Alexander Solms, Dirk Garmann, et al.
Clinical Pharmacokinetics|March 29, 2017
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy SubjectsHelene Hausner, Julie Derving Karsbøl, Anders G Holst, et al.
Clinical Pharmacokinetics|March 5, 2019
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator DrugsGerd Mikus, Kathrin I Foerster, Marlene Schaumaeker, et al.
Clinical Pharmacokinetics|March 7, 2019
Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in ChildrenElizabeth J Thompson, Huali Wu, Anil Maharaj, et al.
Clinical Pharmacokinetics|March 1, 1986
Clinical pharmacokinetics of oral and injectable gold compoundsK L Blocka, H E Paulus, D E Furst
Clinical Pharmacokinetics|February 24, 2017
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail ApproachLaureen A Lammers, Roos Achterbergh, Ron H N van Schaik, et al.
Clinical Pharmacokinetics|February 24, 2017
Clinical Pharmacokinetics of OmbitasvirPrajakta S Badri, Diana L Shuster, Sandeep Dutta, et al.
Clinical Pharmacokinetics|March 2, 2017
Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the LiteratureJoan C Y Ng, Marianna Leung, Alissa J Wright, et al.
Clinical Pharmacokinetics|May 1, 1989
Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokineticsJ E Svirbely, A J Pesce, S Singh, et al.
Clinical Pharmacokinetics|November 24, 2016
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusTim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, et al.
Pageof 348